

In Vitro Leishmanicidal Effect and Gas Chromatography Mass Spectrometry analysis of Chloroform fraction(CF) of *Allium Cepa*

JAHANGIR KHAN ACHAKZAI¹

Ph.D. Scholar

Institute of Biochemistry University of Balochistan
Quetta, Pakistan

MUHAMMAD ANWARPANEZAI

Director

Institute of Biochemistry University of Balochistan
Quetta, Pakistan

ABDUL MANAN KAKAR

Ph.D. Scholar

Institute of Biochemistry University of Balochistan
Quetta, Pakistan

JAVED KHAN

Ph.D. Scholar

Department of Microbiology, Quaid-i-Azam University
Islamabad, Pakistan

Abstract:

The Gas Chromatography and Mass Spectrometry study shown that chloroform fraction (CF) of Allium cepa comprises of 26 compounds which shown effect against Leishmania major (DESO). Inhibitory concentrations observed for chloroform fraction (CF) of Allium cepa ($IC_{50}=73.3 \pm 2.2 \mu g/ml$). In the course of this assay, Amphotericin B ($IC_{50}=0.29 \pm 0.05 \mu g/ml$) as well as pentamidine ($IC_{50}=5.09 \pm 0.09 \mu g/ml$) have been used as positive control drugs to compare the parasite inhibition with that by the chloroform fraction (CF) of Allium cepa. During this bioassay, Incubation temperature and

¹ Corresponding author: jahangir.biochemist@yahoo.com

Incubation period were 22C°and 72hours. Methanol extract (ME), Hexane fraction (HF), Ether fraction (EF), and Diethyl ether fraction (DEF) of Allium ceparevealed noleishmanicidal effect.

Key words: chloroform fraction (CF); Gas Chromatography and Mass Spectrometry; Leishmania major; Amphotericin B; pentamidine

INTRODUCTION

Leishmaniasis forms a variety of multifaceted diseases. Because of defence system developed by the host and different varieties of parasite, it can lead to syndromes which can range from slight self-limiting cutaneous lesion to lethal visceral diseases. The diseases take place in three forms that is: Visceral Leishmaniasis (VL), Mucocutaneous Leishmaniasis (MCL), and Cutaneous Leishmaniasis (CL) [1]. Cutaneous Leishmaniasis has several native alternative expressions for instance, Tropical sore, Oriental sore, Aleppo sore, or Baghdad sore. Cutaneous Leishmaniasis is noticeable through the presence of irritated sores, lesions (ulcers) and enlargement of the lymph nodes on arm, nose, legs or face and lower limbs [2].Mucocutaneous Leishmaniasis (Espundia) creates far-reaching defacing, devastation of mucosa and cartilage of the mouth, nose, ear, and pharynx which leads towards austere disfigurement of the face. Latter on secondary bacterial or fungal infection arises when this disease become worse [3, 4]. Visceral Leishmaniasis “Kala-azar” is a universal infection in which the parasites are capable to occupy the spleen and liver which causes a persistent splenomegaly.[1] [5, 6].Chemotherapy of Leishmaniasis is targeted at reducing illness and death related with the disease. Drugs used for the treatments of Leishmaniasisare pentavalentantimonials; meglumineantimoniate (Glucantime), pentamidine (aromatic diamidine) and sodium stibogluconate (SbV) (Pentostam),

liposomal amphotericin B, (AmBisome), Paromomycin (Humatin) and miltefosine (Miltex) [7, 8, 9, 10,]. Pentavalent antimonial, Pentamidine, Amphotericin B, Paromomycin and Miltefosine are the first line of medications which have been approved for the cure of leishmaniasis [11,12,13,14,15] however, Azoles, Allopurinol, Sitamaquine, and Imiquimod are the medications in experimental trial for the cure of leishmaniasis [16,17,18,19]. *Allium cepa* is one of the important specie of the Liliaceae [20]. *Allium* comprises around five hundred and fifty types [21]. *Allium cepa* is significant for nutritional as well as for medications in “folk medicine”, [22]. In this research study we evaluate the leishmanicidal effect of chloroform fraction (CF) of *Allium cepa*.

MATERIAL AND METHODS

PLANT MATERIAL

Garden-fresh *Allium cepa* were collected from local market of Quetta City, Balochistan, Pakistan. **EXTRACTION OF ALLIUM CEPA**

This research of extraction was completed in the Prof. Dr. M. Anwar Panezai lab, Institute of Biochemistry University of Balochistan Quetta. Five kg of onion also known as *Allium cepa* were soaked in methanol [23] and was kept for six days. During this period, the soaked *Allium cepa* was shaken daily. After the completion of six days, the soaked *Allium cepa* in methanol was filtered and the filtrate containing methanol was vaporized in the rotary evaporator. Finally, the crude methanolic extract (ME) was collected and measured 165.42 gm [24].

FRACTIONATION OF ALLIUM CEPA

One gm from crude methanolic extract (ME) used for leishmanicidal effect and GC-MS analysis while the remaining extract was fractionated with the help of different solvents such

as n-Hexane, water, ether, chloroform, diethyl ether. In a separatory funnel, with methanolic crude extract, n-Hexane and water have been added. After shaking, n-Hexane layer has been separated from aqueous layer. Both n-Hexane and aqueous layer were separately vaporized in the rotary evaporator to get n-Hexane fraction (HF), and aqueous fraction (AF).

FRACTIONATION OF n-HEXANE FRACTION (HF)

One gm from n-Hexane fraction (HF) used for leishmanicidal effect and GC-MS analysis while the remaining fraction was fractionated with the help of different solvents such as ether, chloroform, diethyl ether.

FORMATION OF ETHER FRACTION (EF)

In a separatory funnel, with n-Hexane fraction (HF), n-Hexane and ether have been added. After shaking, n-Hexane layer has been separated from ether layer. Both n-Hexane and ether layer were separately vaporized in the rotary evaporator to get n-Hexane fraction (HF) and ether fractions (EF). Ether fraction (EF) was used for leishmanicidal effect.

FORMATION OF CHLOROFORM FRACTION (CF)

In a separatory funnel, with n-Hexane fraction (HF), n-Hexane and chloroform have been added. After shaking, n-Hexane layer has been separated from chloroform layer. Both n-Hexane and chloroform layer were separately vaporized in the rotary evaporator to get n-Hexane fraction (HF) and chloroform fraction (CF). Chloroform fraction (CF) was used for leishmanicidal effect.

FORMATION OF DIETHYL ETHER FRACTION

In a separatory funnel, with n-Hexane fraction (HF), n-Hexane and diethyl ether have been added. After shaking, n-Hexane layer has been separated from diethyl ether layer. Both n-Hexane and diethyl ether layer were separately vaporized in the

rotary evaporator to get n-Hexane fraction (HF) and diethyletherfraction (DEF). DiethylEther fraction (DEF) was used forleishmanicidal effect.

Finally, methanolicextract (ME), n-Hexane fraction (HF), ether fraction (EF), chloroform fraction (CF) anddiethylether fraction (DEF) were prepared for leishmanicidal effect.

ANTILEISHMANIAL ACTIVITY OF *ALLIUM CEPA* FRACTION

The test was performed according to Atta-urRahman[25]. Concisely, L. major promastigotes in stationary phase were seeded at 40,000 parasites/400ul/well in 24-“well plate i]n RPMI-FCS”. The extracts were dissolved in DMSO and added further 400ul/well to give final concentrations of 1mg per ml and serial two-fold dilution thereof. Promastigotes were incubated over a period of 6 days at 25 C° and the amount of parasites in each well determined on days 2, 4 and 6 of experiment using neubar chamber under a microscope. Amphotericin B (0.5 mg/ml (was used as positive control, culture media was used as negative control and DMSO was used as solvent control.

GAS CHROMATOGRAPHY MASS SPECTROMETRY (GC-MS) ANALYSIS TRIPLE QUADRUPOLE ACQUISITION METHOD-MS PARAMETERS

For identification and quantification of *Allium cepa* compounds: 2 ul of *Allium cepa* extract or fraction was directly injected into the gas chromatograph mod.6890N Network GC System (Agilent Technologies “Palo Alto, CA”) together in the presence of mass spectrometer mod. “5973 Network Mass Selective Detector” (Agilent Technologies “Palo Alto, CA”) and furnished in the presence of “a column HP-5MS (30 m length, 0.25 mm interior diameter, 0.25 um film width” Agilent Technologies, “Palo Alto, CA”). Helium gas was off. Injection was made into a

split-splitless injector (split ratio 30:1) at 250 C°. The oven program was the following: “70 C° for 3 min then 6 C° /min to 180 for 5 min, then 6 C° /min to 280 C° for 10 min, then 8 C° /min to 290 C° for 20 min”. The MSD transfer line was set at a temperature of 250 C° ; MSD temperature quadrupole was of 150 C° and ionization temperature was 230 C°, Mass spectra were seventy electrovolts and scan achievement was accomplished in the series between thirty five and 300m/z. The identification of the components of the *Allium cepa* extract or fraction was assigned by matching their “mass spectra with those available in the libraries NIST 02 and WILEY”[26].

RESULTS

ANTILEISHMANIAL ACTIVITY OF *ALLIUM CEPA* FRACTIONS

Antileishmanial activity of *Allium cepa* extract and fractions was performed against *Leishmania major* (DESO). Effective antileishmanial activity was observed for chloroform fraction (CF) while other extract and fractions such as Methanol extract (ME), Hexane fraction (HF), Ether fraction (EF), and Diethyl ether fraction (DEF) exhibited no antileishmanial activities. Inhibitory concentration of chloroform fraction (CF) observed (IC₅₀=73.3 ±2.2ug/ml). In this bioassay, Amphotericin B (IC₅₀= 0.29 ± 0.05 ug/ml) and pentamidine (IC₅₀=5.09 ±0.09 ug/ml) were used as positive control drugs to compare the parasite inhibition with that by the *Allium cepa* extract and fractions. This activity was perceived under Incubation period 72 h and Incubation Temperature 22 C°.

Table 1: Antileishmanial activities of extracts and fractions of *Allium cepa*

S.NO	Name of extracts	IC50 ug/ml
1	ME	-
2	HF	-
3	EF	-
4	CF	73.3 ±2.2ug/ml
5	DEF	-
6	Amphotericin B	0.29 ± 0.05 ug/ml
7	pentamidine	5.09 0.09 ug/ml

CHEMICAL COMPOSITION OF CHLOROFORM FRACTION (CF)

The chloroform fraction (CF) which showed antileishmanial activity has been analyzed by Gas Chromatography Mass Spectrometry and results are represented in tables. Chloroform fraction (CF) consists of 26 compounds. 26 compounds were evaluated by RT matching with library and MS spectra.

Table 2: Molecular formula, Molecular mass, Structure, m/z and RT of 1-7 compounds in chloroform fraction (CF)








Compd	Molecular formula	Molecular mass	Structure	m/z	RT
1	C13H13NO2	215		93	11.72
2	C15H30O2	242		74	22.351
3	C17H34O2	270		74	28.038
4	C19H34O2	294		67.1	32.066
5	C19H36O2	296		55.1	32.243
6	C19H36O2	296		55.1	32.331
7	C19H38O2	298		74	32.726

Table 3: Molecular formula, Molecular mass, Structure, m/z and RT of 8-14 compounds in chloroform fraction (CF)












Compd	Molecular formula	Molecular mass	Structure	m/z	RT
8	C ₂₃ H ₄₄ O ₂	352		55.1	35.834
9	C ₂₂ H ₄₄ O ₂	340		74	36.253
10	C ₁₀ H ₂₀ O	156		59.1	36.769
11	C ₂₆ H ₅₄ O	382		55.1	37.261
12	C ₁₄ H ₃₀ O	214		73	38.54
13	C ₂₄ H ₃₈ O ₄	390		149	39.5
14	C ₁₆ H ₁₅ NO	237		237	40.1

Table 4: Molecular formula, Molecular mass, Structure, m/z and RT of 15-21 compounds in chloroform fraction (CF)

Compd	Molecular formula	Molecular mass	Structure	m/z	RT
15	C ₁₇ H ₁₇ NO	251		251.1	40.61
16	C ₂₄ H ₃₈ O ₄	390		149	41.13
17	C ₃₄ H ₅₈ O ₄	530		149	41.92
18	C ₂₂ H ₄₃ NO ₄	385		116	43.1

Jahangir Khan Achakzai, Muhammad Anwarpanezai, Abdul Manan Kakar, Javed Khan- **In Vitro Leishmanicidal Effect and Gas Chromatography Mass Spectrometry analysis of Chloroform fraction(CF) of *Allium Cepa***




19	C27H46O	386		43.1	47.47
20	C26H42O	370		55.1	49.02
21	C15H24	204		69.1	51.434

Table 5: Molecular formula, Molecular mass, Structure, m/z and RT of 22-26 compounds in chloroform fraction (CF)






Compd	Molecular formula	Molecular mass	Structure	m/z	RT
22	C15H23Br	283		69.1	53.967
23	C13H14O3	218		218.1	55.452
24	C20H16N2O2	316		316.2	60.324
25	C9H9NO	147		147	60.365
26	C14H18O2	218		95	66.119

Table 6: Mass spectra of 1-7 compounds in chloroform fraction (CF)

Compd	m/z (% Relative abundance)
1	215(M ⁺),95(14440), 93(46197), 85 (2360.8), 83.1 (3233.4), 77 (2272.6), 76 (4344.3), 57.1 (19890), 49 (3199), 48(2804), 43.1 (15559)
2	242(M ⁺),143.1(4129.5), 87 (22208),75.1(5600.6), 74 (34315), 69.1 (4488.3), 59.1 (4065), 57.1 (5013.8),55.1(8950.7), 43.1 (10207), 41.1 (5431.1)
3	270(M ⁺),143.1(191427.9),87 (982781.6),75.1 (265683.6), 74 (1473550), 69.1(201160.1), 59.1(142191.7), 57.1 (242415.4), 55.1 (416671.7), 43.1 (396394.8), 41.1(195992.4)
4	294(M ⁺),96(67181.3), 95 (107656.9), 82 (87786.3), 81 (162562.4), 79(79615.2), 69.1(64992.5), 68.1(87309.7), 67.1 (206363.5), 55.1 (149260.7), 54.1(86297.8)
5	296(M ⁺),97(281998.9), 96(258945.3), 87 (272790.8), 84 (264819.1), 83.1 (343315.6), 74 (387162.9), 69.1(450111.5), 67.1 (262389.1), 55.1 (743192), 43.1 (274578.7)
6	296(M ⁺),97(21334), 96(19655), 87 (20334), 83.1 (26118), 74 (29895) , 69.1(33821),67.1(21657), 55.1 (60695), 43.1 (25131)
7	298(M ⁺), 143.1(40205.2), 87 (195141.5),83.1(27565.6),75.1(62133.7), 74

Jahangir Khan Achakzai, Muhammad Anwarpanezai, Abdul Manan Kakar, Javed Khan- **In Vitro Leishmanicidal Effect and Gas Chromatography Mass Spectrometry analysis of Chloroform fraction(CF) of *Allium Cepa***

(290450.7),69.1(46621.6), 57.1 (60433.3), 55.1(89768.1)

Table 7: Mass spectra of 8-14 compounds in chloroform fraction (CF)

compd	m/z (% Relative abundance)
8	352(M ⁺), 97(3049.2), 83.1 (3774),74 (2757.8), 73 (6972.1), 72 (5157), 71.1 (3724.9),69.1(4327.3),57.1(5377.4),55.1(8499.4), 43.1 (6041.3)
9	340(M ⁺),143.1(3957.7), 87(18461), 83.1 (3842.2), 75.1 (6727.5),74(26340), 69.1 (4914.2), 57.1 (6218.3),55.1(8879.5),43.1(9331.1), 41.1 (3710)
10	156(M ⁺),83.1(2373.8), 81 (2309), 72 (8354.3), 69.1(2100.3), 67.1(1883.9), 59.1(14445), 55.1(5201.7), 44(1845.5), 43.1(3342.9), 41.1 (2694.7)
11	382(M ⁺),251.1(1781.3), 97 (2681), 83.1 (3142.6), 71.1(2417.2), 70.1 (1522.6), 69.1(2266.2), 57.1(2941.1), 56.1(1688.4), 55.1 (3509.4), 43.1(2495)
12	214(M ⁺),98(3277.6), 97 (3544.1), 83.1 (4845.1), 73(14963), 69.1 (4772.7), 57.1(3416.7), 55.1 (10820), 45 (2867.6), 43.1(4189.3), 41.1 (2779.4)
13	390(M ⁺), 167(119897.5), 150 (43304.8), 149(392165.7), 113(40650.1), 71.1(106907), 70.1 (90466.5), 57.1(165805.4), 55.1(64162.4), 43.1(83894.1), 41.1(45352.9)
14	237(M ⁺),237(3687.9), 236.1 (1644.6), 160(2608.8), 132 (1752.3), 117(1725.8), 111.1(1398.2), 107 (2675.6), 97(2352.9), 83.1(2454),71.1(2370.6)

Table 8: Mass spectra of 15-21 compounds in chloroform fraction (CF)

compd	m/z (% Relative abundance)
15	251(M ⁺), 252.1(107316.9), 251.1(605137.9), 250.1 (257931.7), 174.1(360281.7), 146.1(178911.7),130(105656.7), 121(186905.4), 105(111206.7), 77 (317788.8), 51.1 (111913.4)
16	390(M ⁺), 162(3423.3), 150 (3599.5), 149(13019), 132(2682.6), 113 (2326.2),104 (2705.8), 71.1 (5239.4), 57.1 (6806.1), 55.1(4014.1), 43.1(4480.4)
17	530(M ⁺), 149(18515), 127(10710), 109(4527.6), 108(5495.5), 83.1(6002.7), 71.1(7071.8),69.1(4518.6), 57.1(8306.6), 55.1(5357.2), 43.1(15671)
18	385(M ⁺),133.9(4714.6),116(4814.2), 97 (2257.3), 88(2995.1), 83.1 (2668.7), 69.1 (1754.5),67.1(1839), 56.1 (1674.7), 55.1 (3591.4), 43.1 (2405.4)
19	386(M ⁺),107(3719.9),105(4160.5),95(4661.8), 93 (3123.8),91(3200.9), 81 (4478.4), 79(3601.5), 57.1 (3755.7), 55.1(4180.7), 43.1 (5025.2)
20	370(M ⁺),399.4(24977), 119(13415), 107 (13336), 105(15780), 95 (22140), 83.1(14822), 81(14718), 69.1(19287), 57.1 (21514), 55.1 (26423)
21	204(M ⁺), 109(30049), 107(33329), 95 (48101), 93 (34056), 91 (29122), 81 (41142), 79(30006), 69.1(83050), 55.1(56910), 41.1 (28791)

Table 9: Mass spectra of 22-26 compounds in chloroform fraction (CF)

compd	m/z (% Relative abundance)
22	283(M ⁺), 135(715.5), 121(4761.9), 109(6506.1), 105(5549.9), 95(9577.8), 93 (6855.6), 81(7868.7), 79 (5861.8), 69.1(15446), 67.1(48315)
23	218(M ⁺), 281(1176), 218.1 (3086.2), 203 (2036.6), 119(1251.5), 109 (1241.5), 107 (1119.4), 105 (1482.2), 69.1 (1229.4), 55.1 (1171.1), 43.1(1560.7)
24	316(M ⁺), 316.9(1564.9), 316.2(4130.3), 175.1(1172.9), 163.1 (823.2), 159(1297.1), 135 (2008.2), 129 (1169.6), 109(953), 107 (1233.5), 59.1(1001.6)
25	147(M ⁺), 207.9(785.3), 194.9 (615.8), 149(1166.7), 147(2605.2), 131(1554.5), 119(1907.9), 117(1463.9), 91 (2363.2), 58.1(1245.8), 53 (782.6)
26	(M ⁺), 192.9(622.7), 190.9 (728.7), 147(677.4), 133 (952.5), 119 (730.2), 117 (622.9), 105 (961.3), 96 (642.2), 95(1362.9), 59.1(755.6)

ACKNOWLEDGEMENT

The authors are thankful to Hussian Ebrahim Jamal (HEJ), Research Institute of Chemistry, University of Karachi, Pakistan, for providing GC-MS and leishmanicidal facilities and Institute of Biochemistry, University of Balochistan, Quetta, Pakistan, for providing lab facilities.

REFERENCES

1. **Bari, A. U.** Clinical spectrum of cutaneous leishmaniasis: an overview from Pakistan. *Dermatology Online Journal*. 2012; 18: 4.
2. **Vandana, M.,** Balachandran, C., Raghavendra, R., Sumeet, K. and Laxmi, I. Diffuse cutaneous leishmaniasis in HIV. *Dermatology Online Journal*. 2009; 15: 9.
3. **Davies, C. R.,** Kaye, P., Croft, S. L. and Sundar, S. Leishmaniasis: new approaches to disease control. *British Medical Journal*. 2003; 326: 377 - 382.
4. **Sundar, S.,** Jha, T. K., Thakur, C. P., Sinha, P. K. and Bhattacharya, S. K. Injectable paromomycin for visceral leishmaniasis in India. *The New England Journal of Medicine*. 2007; 356: 2571 – 2581
5. **Chappuis, F.,** Shyam, S., Asrat H., Hashim, G., Suman, R., Rosanna, W. P., Jorge, A. and Marleen, B. Review: visceral leishmaniasis. What are the needs for diagnosis, treatment and control? Nature Publishing Group. 2007; 5: 873 - 882.
6. **Craig, G. S.** Drugs, diseases and procedures: leishmaniasis differential diagnoses. *Medical News, Perspectives and Full Text Journal Articles*. 2011; 377: 477 - 86.
7. **Blum, J.,** Desjeux, P., Schwartz, E., Beck, B. and Hatz, C. Treatment of cutaneous leishmaniasis among travellers.

- Journal of Antimicrobial Chemotherapy*. 2004; 53: 158 - 166.
8. **Chan, C.**, Yin, H., Garforth, J., McKie, J. H., Jaouhari, R., Speers, P., Douglas, K. T., Rock, P. J., Yardley, V., Croft, S. L. and Fairlamb, A. H. Phenothiazine Inhibitors of 88 trypanothionereductase as potential antitrypanosomal and Antileishmanial drugs. *Journal of Medicinal Chemistry*.1998; 41: 148 - 56.
 9. **Gilles, H. M.** Protozoal diseases. *ARNOLD Publisher, London*. 1999;**64**: 413-503.
 10. **Smith, A.C.**, Yardley, V., Rhodes, J. And Croft, S. L. Activity of the novel Immunomodulatory compound tucaresol against experimental visceral leishmaniasis. *Journal of Antimicrobial Agent Chemotherapy*. 2000;**44**: 1494 - 1498.
 11. **Croft, S. L.** and Coombs, G. H. Leishmaniasis: current chemotherapy and recent Advances in the search for novel drugs. *Trends in Parasitology*. 2003;**19**: 502 - 512.
 12. **Maes, L.**, Germonprez, N., Quirijnen, L., Puyvelde, L.V., Cos, P. And Berghe, D.V. Comparative activities of the triterpenesaponinmaesabalide III and liposomal Amphotericin B (AmBisome) against Leishmaniadonovani in hamsters. *Journal of Antimicrobial Agents and Chemotherapy*. 2004;**48**: 2056 - 2060.
 13. **Laurence, L.**, John, S. L. and Keith, L. P. (Editors) Goodman and Gilman's. The Pharmacological basis of therapeutics. 11th ed. McGraw-Hill, New York, 2006; PP. 1178 – 97
 14. **Miguel, D.C.**, Yokoyama-Yasunaka¹, J. K. U., Andreoli, W. K., Mortara, R. A. And Uliana, S. R.B. Tamoxifen is effective against Leishmania and induces a rapid alkalization of parasitophorous vacuoles harbouringLeishmania (L.) Amanuensis amastigotes.

- Journal of Antimicrobial Chemotherapy*. 2007;60: 526 - 34.
15. **WHO**. The selection and use of essential medicines. *Report series***946:2007**; pp.36.
 16. **Antony, J. D.** and Lukasz, K. Recent advances in antileishmanial drug Development. *Current Opinion and Investment on Drugs*. 2005;**6**: 163-69.
 17. **Piscopo, T.V.** and Mallia, A.C. Leishmaniasis. *Postgraduate Medical Journal*. 2006;**82**: 649 - 657.
 18. **Croft, S. L.,** Sundar, S. And Fairlam, A. H. Drug resistance in leishmaniasis. *Clinical Microbiology Reviews*. 2006;**19**: 111 - 126.
 19. **Firooz, A.,** Khamesipour, A., Ghoorchi, M. H., Nassiri-Kashani, M., Eskandari, S. E., Khatami, A., Hooshmand, B., Gorouhi, F., Rashighi-Firoozabadi, M.AndDowlati,Y.Imiquimod in combination with meglumineantimoniate for cutaneous Leishmaniasis. A randomized assessor-blind controlled trial. *Archives of Dermatology*. 2006;142: 1575 - 1579.
 20. **Strasburger, E.,** Sitte, P., Weiler, E.W., Kadereit, J.W., Bresinsky, A., Körner, C. Lehrbuch der BotanikfürHochschulen. *Gustav Fischer Verlag Stuttgart, New York*1978; **95**.
 21. **Dahlgren, R.M.,** Clifford, T., Yeo, P. The families of the monocotyledons. *Springer-Verlag, Berlin, Heidelberg, New York*.1985.
 22. **Hegi, G.** Illustrierte Flora von Mitteleuropa, Vol II, (ed. Suessenguth K.) J.F.LehmannsVerlag, München, Berlin;1939
 23. **JehanBakht,** Shehla khan and Mohammad Shafi. Antimicrobial potentials of fresh *Allium cepa* against gram positive and gram negative bacteria and fungi. *Pak. J. Bot*2013; **45(S1)**: 1-6.
 24. Jahangir khan Achakzai and Muhammad Anwar. GC-MS Analysis and Antileishmanial Activity of

dichloromethane fraction of *Allium cepa* (DFAC) in Vitro. *International Journal of Pharma and Bio Sciences*.2016;7(2):40-51

25. **Atta-ur Rahman**, M. I. Chaudhary and W. Thompson,., Bioassay Techniques for Drug, *Harwood Academic publishers, The Netherland*, 2001; pp: 60.
26. **Eman Ahmed El-Wakil.**, Mortada Mohamed El-Sayed, Ezzat El-Sayed Abdel-Lateef. GC-MS Investigation of Essential oil and antioxidant activity of Egyptian White Onion (*Allium cepa* L.). *International journal of pharma sciences and research IJPSR*. 2015;**6**: 3.